Literature DB >> 2957907

Risk of ventricular arrhythmias in left ventricular hypertrophy: the Framingham Heart Study.

D Levy, K M Anderson, D D Savage, S A Balkus, W B Kannel, W P Castelli.   

Abstract

The association of ventricular arrhythmias with left ventricular (LV) hypertrophy was examined in 6,218 participants in the Framingham Heart Study. Electrocardiographic (ECG) LV hypertrophy was present in 171 subjects and echocardiographic hypertrophy was detected in 869. Echocardiographic LV hypertrophy was associated with increased risk for each of 6 ventricular arrhythmia grades in men (relative risk up to 8.9, p less than 0.01), and 4 of 6 grades in women (p less than 0.05). Similarly, men with ECG LV hypertrophy were at increased risk for 4 of 6 arrhythmia grades (p less than 0.05). However, owing to low prevalence ECG LV hypertrophy was not associated with arrhythmia in women. After adjustment for age, sex, systolic blood pressure, valvular heart disease, angina pectoris and acute myocardial infarction, the association of echocardiographic but not ECG LV hypertrophy with ventricular arrhythmia remained significant (p less than 0.001). Thus, echocardiographic LV hypertrophy is more prevalent and more sensitive for ventricular arrhythmias than ECG LV hypertrophy.

Entities:  

Mesh:

Year:  1987        PMID: 2957907     DOI: 10.1016/0002-9149(87)90305-5

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  50 in total

Review 1.  Regression of left ventricular hypertrophy; what are appropriate therapeutic objectives?

Authors:  D J Sheridan; M P Kingsbury; N A Flores
Journal:  Br J Clin Pharmacol       Date:  1999-02       Impact factor: 4.335

Review 2.  What do we know and we do not know about cardiovascular autonomic neuropathy in diabetes.

Authors:  Rodica Pop-Busui
Journal:  J Cardiovasc Transl Res       Date:  2012-05-30       Impact factor: 4.132

Review 3.  Reserpine: a relic from the past or a neglected drug of the present for achieving cost containment in treating hypertension?

Authors:  G J Magarian
Journal:  J Gen Intern Med       Date:  1991 Nov-Dec       Impact factor: 5.128

4.  The impact of left ventricular hypertrophy on survival in candidates for liver transplantation.

Authors:  Sachin Batra; Victor I Machicao; John S Bynon; Shivang Mehta; Rajasekhar Tanikella; Michael J Krowka; Steven Zacks; James Trotter; Kari E Roberts; Robert S Brown; Steven M Kawut; Michael B Fallon
Journal:  Liver Transpl       Date:  2014-06       Impact factor: 5.799

5.  Left ventricular hypertrophy and risk of fatal and non-fatal stroke. EUROSTROKE: a collaborative study among research centres in Europe.

Authors:  M L Bots; Y Nikitin; J T Salonen; P C Elwood; S Malyutina; A Freire de Concalves; J Sivenius; A Di Carlo; P Lagiou; J Tuomilehto; P J Koudstaal; D E Grobbee
Journal:  J Epidemiol Community Health       Date:  2002-02       Impact factor: 3.710

6.  Caveolin-3 Overexpression Attenuates Cardiac Hypertrophy via Inhibition of T-type Ca2+ Current Modulated by Protein Kinase Cα in Cardiomyocytes.

Authors:  Yogananda S Markandeya; Laura J Phelan; Marites T Woon; Alexis M Keefe; Courtney R Reynolds; Benjamin K August; Timothy A Hacker; David M Roth; Hemal H Patel; Ravi C Balijepalli
Journal:  J Biol Chem       Date:  2015-07-13       Impact factor: 5.157

7.  Risk factor paradox: No prognostic impact of arterial hypertension and smoking in patients with ventricular tachyarrhythmias.

Authors:  Kathrin Weidner; Michael Behnes; Jonas Rusnak; Gabriel Taton; Tobias Schupp; Linda Reiser; Armin Bollow; Thomas Reichelt; Dominik Ellguth; Niko Engelke; Philip Kuche; Jorge Hoppner; Ibrahim El-Battrawy; Siegfried Lang; Christoph A Nienaber; Kambis Mashayekhi; Dennis Ferdinand; Christel Weiß; Martin Borggrefe; Ibrahim Akin
Journal:  Cardiol J       Date:  2018-12-19       Impact factor: 2.737

8.  Regional distribution of hyperpolarization-activated current (If) and hyperpolarization-activated cyclic nucleotide-gated channel mRNA expression in ventricular cells from control and hypertrophied rat hearts.

Authors:  María Fernández-Velasco; Nora Goren; Gemma Benito; Javier Blanco-Rivero; Lisardo Boscá; Carmen Delgado
Journal:  J Physiol       Date:  2003-09-26       Impact factor: 5.182

Review 9.  Left ventricular hypertrophy. Prevalence in older patients and management.

Authors:  E Paciaroni; A Fraticelli
Journal:  Drugs Aging       Date:  1995-04       Impact factor: 3.923

10.  Long-term treatment of spontaneously hypertensive rats with PD123319 and electrophysiological remodeling of left ventricular myocardium.

Authors:  Xiao Ying; Guan Kai-Pan; Long Wei-Qing; Peng Long-Yun; Wu De-Xi; Huang Zhi-Bin
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2016-09-14       Impact factor: 3.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.